Ligandal is a regenerative medicine, targeted delivery and medical countermeasures related biodefense company developing unique approaches for a variety of diseases. Our lead candidate is a peptide for the early treatment and prophylaxis against COVID-19.
OUR COVID-19 PARTNERS
|
|
omicron covid variant
pdb file download
(shown compared to wildtype and overlaid with vir and regeneron antibodies)
| sars-cov-2_omicron_vs._wildtype_w_vir-regn_fabs_ligandal_12.1.2021.pse |
peptide antidotes to sars-cov-2 (covid-19)
https://www.biorxiv.org/content/10.1101/2020.08.06.238915v2
Have Ligandal Found a COVID-19 Treatment and SARS-CoV-2 Vaccine?
https://techround.co.uk/news/ligandal-covid-19-treatment-sars-cov-2-vaccine/
Peptide Scaffold Antidotes and Vaccines for SARS-CoV-2 and Biodefense
PEPTIDE vaccine SCAFFOLDSOur peptide scaffolds will bolster the immune response to SARS-CoV-2.
|
ACE2 viral entry inhibitionThese scaffolds will also bind to the ACE2 receptor, preventing viral entry.
|
Immunoepitope mappingThe scaffolds contain multiple viral immunogenic domains.
|